A_2A adenosine receptors are up-regulated in lymphocytes from amyotrophic lateral sclerosis patients

References

• Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942–55.
   PubMed Web of Science ®Google Scholar
• Eisen A. Amyotrophic lateral sclerosis is a multifactorial disease. Muscle Nerve. 1995;18:74–52.
   PubMedGoogle Scholar
• Siciliano G, Carlesi C, Pasquali L, Piazza S, Pietracupa S, Fornai L, et al. Clinical trials for neuroprotection in ALS. CNS & Neurol Disord Drug Targets. 2010;9:305–13.
   PubMed Web of Science ®Google Scholar
• Perry JJ, Shin DS, Tainer JA. Amyotrophic lateral sclerosis. Adv Exp Med Biol. 2010;685:9–20.
   PubMed Web of Science ®Google Scholar
• Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7:639–49.
   PubMed Web of Science ®Google Scholar
• Rothstein JD. Current hypothesis for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009;65:S3–9.
   PubMed Web of Science ®Google Scholar
• Volontè C, Amadio S, Cavaliere F, D’Ambrosi N, Vacca F, Bernardi G. Extracellular ATP and neurodegeneration. Curr Drug Targets CNS Neural Disord. 2003;2:403–12.
   PubMedGoogle Scholar
• Burnstock G. Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov. 2008;7:575–90.
   PubMed Web of Science ®Google Scholar
• Varani K, Vincenzi F, Tosi A, Gessi S, Casetta I, Granieri G, et al. A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson’s disease. FASEB J. 2010;24:587–98.
   PubMed Web of Science ®Google Scholar
• Volontè C, Apolloni S, Carrì MT, D’Ambrosi N. ALS: focus on purinergic signalling. Pharmacology & Therapeutics. 2011;132:111–22.
   PubMedGoogle Scholar
• Haskò G, Linden J, Cronstein BN, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discover. 2008;7:759–70.
   PubMed Web of Science ®Google Scholar
• Gessi S, Merighi S, Varani K, Borea PA. Adenosine receptors in health and disease. Adv Pharmacol. 2011;61:41–75.
   PubMedGoogle Scholar
• Ramekers BP, Riksen NP, van der Hoeven JG, Smits P, Pickkers P. Modulation of innate immunity by adenosine receptor stimulation. Shock. 2011;36:208–15.
   PubMedGoogle Scholar
• Varani K, Laghi-Pasini F, Camurri A, Capecchi PL, Maccherini M, Diciolla F, et al. Changes of peripheral A2A adenosine receptors in chronic heart failure and cardiac transplantation. FASEB J. 2003;17:280–2.
   PubMedGoogle Scholar
• Gessi S, Cattabriga E, Avitabile A, Gafa’ R, Lanza G, Cavazzini L, et al. Elevated expression of A3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clin Cancer Res. 2004;10:5895–901.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). Neurol Sci. 1999;169:13–21.
   Google Scholar
• Brinkmann JR, Andres P, Mendoza M, Sanjak M. Guidelines for the use and performance of quantitative outcome measures in ALS clinical trials. J Neurol Sci. 1997;147: 97–111.
   PubMed Web of Science ®Google Scholar
• Varani K, Massara A, Vincenzi F, Tosi A, Padovan M, Trotta F, et al. Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumour necrosis factor alpha but not methotrexate. Arthritis Rheum. 2009;60:2880–91.
   PubMed Web of Science ®Google Scholar
• Varani K, Padovan M, Vincenzi F, Targa M, Trotta F, Govoni M, et al. A2A and A3 adenosine receptor expression in rheumatoid arthritis: up-regulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release. Arthritis Res Ther. 2011;13:R197.
   PubMed Web of Science ®Google Scholar
• Varani K, Vincenzi F, Tosi A, Targa M, Masieri FF, Ongaro A, et al. Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes. Br J Pharmacol. 2010;160:101–15.
   PubMedGoogle Scholar
• Varani K, Merighi S, Gessi S, Klotz KN, Leung E, Baraldi PG, et al. [3H]-MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors. Mol Pharmacol. 2000;57:968–75.
   PubMed Web of Science ®Google Scholar
• Varani K, Gessi S, Merighi S, Vincenzi F, Cattabriga E, Benini A, et al. Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol. 2005;70:1601–12.
   PubMed Web of Science ®Google Scholar
• Simola N, Morelli M, Pinna A. Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions. Curr Pharm Des. 2008;14:1475–89.
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Haegawa K, Kondo T, Kuno S, Yamamoto Y. Japanese Istradefylline Study Group. Clinical efficacy of istradefylline (KW 6002) in Parkinson's disease: a randomized, controlled study. Mov Disord. 2010; 25:1437–43.
   PubMed Web of Science ®Google Scholar
• Ciccarelli R, Ballerini P, Sabatino G, Rathbone MP, D’Onofrio M, Caciagli F, et al. Involvement of astrocytes in purine-mediated separative processes in the brain. Int J Dev Neurosci. 2001;19:395–414.
   PubMed Web of Science ®Google Scholar
• Halassa MM, Haydon PG. Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior. Annu Rev Physiol. 2010;72:335–55.
   PubMed Web of Science ®Google Scholar
• Mojsilovic-Petrovic J, Jeong GB, Crocker A, Arneja A, David S, Russel DS, et al. Protecting motor neurons from toxic insult by antagonism of adenosine A2A and Trk receptors. J Neurosci. 2006;26:9250–63.
   PubMed Web of Science ®Google Scholar
• Chen JF, Sonsalla PK, Pedata F, Melani A, Domenici MR, Popoli P, et al. Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and ‘fine tuning’ modulation. Prog Neurobiol. 2007;83:310–31.
   PubMed Web of Science ®Google Scholar
• Popoli P, Blum D, Martire A, Ledent C, Ceruti S, Abbracchio MP. Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington’s disease. Prog Neurobiol. 2007;81:331–48.
   PubMedGoogle Scholar
• Komaki S, Ishikawa K, Arakawa Y. Trk and cAMP-dependent survival activity of adenosine (A2A) agonist CGS21680 on rat motor neurons in culture. Neurosci Lett. 2012;522:21–4.
   PubMedGoogle Scholar
• Yanpallewar SU, Barrick CA, Buckley H, Becker J, Tessarollo L. Deletion of the BDNF truncated receptor TrkB.T1 delays disease onset in a mouse model of amyotrophic lateral sclerosis. PLoS One. 2012;7:e39946.
   Google Scholar
• Impellizzeri D, Di Paola R, Esposito E, Mazzon E, Paterniti I, Melani A, et al. CGS 21680, an agonist of the adenosine (A2A) receptor, decreases acute lung inflammation. Eur J Pharmacol. 2011;668:305–16.
   PubMed Web of Science ®Google Scholar
• Garcia GE, Truong LD, Chen JF, Johnson RJ, Feng L. Adenosine (A2A) receptor activation prevents progressive kidney fibrosis in a model of immune-associated chronic inflammation. Kidney Int. 2011;80:378–88.
   PubMed Web of Science ®Google Scholar
• Montesinos MC, Desai A, Delano D, Chen JF, Fink JS, Jacobson MA, et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum. 2003;48:240–7.
   PubMed Web of Science ®Google Scholar